Form 6-K Evotec SE For: Aug 13

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of August, 2025

 

COMMISSION FILE NUMBER 001-34041

 

Evotec SE
(Translation of registrant’s name into English)

 

Essener Bogen 7

22419 Hamburg

Germany

Tel: +49 40 560810
(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F: Form 20-F x Form 40-F ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨

 

 

 

On August 13, 2025, Evotec SE (the “Company”) issued a press release announcing the Company’s financial results and business updates for the first six months of 2025 attached hereto as Exhibit 99.1.

 

EXHIBIT INDEX

 

Exhibit	Description of Exhibit
99.1	Evotec SE reports H1 2025 results: Strong progress on strategy execution

 

 

SIGNATURE

 

Pursuant to the requirements, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

	Evotec SE
	By:	/s/ Paul Hitchin
		Name: Paul Hitchin
		Title: Chief Financial Officer

 

Date: August 13, 2025

 

 

ATTACHMENTS / EXHIBITS

EXHIBIT 99.1

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Distribution Dates and Amounts Announced for Eaton Vance Closed-End Funds
• AM Best Affirms Credit Ratings of Mitsui Sumitomo Insurance Company, Limited and Aioi Nissay Dowa Insurance Company Limited; Assigns Credit Ratings to MSIG Specialty Insurance America, Inc.
• NetworkNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Editorial on Advanced Cancer Drug Delivery